

Table S1 - Cause of death (everolimus vs. control)

Cause of death, <i>n</i> (%)	Everolimus n=242	Control n=107	p value*
Cardiovascular	13 (5.4)	1 (0.9)	0.05
Cancer	14 (5.8)	5 (4.7)	0.7
Infection	7 (2.9)	3 (2.8)	1.0
Other	7 (2.9)	4 (3.7)	0.7
Total	41 (17)	13 (12)	0.3

*p value calculated using Pearson's chi-square test

Table S2 – Subgroup analyses: Hazard ratio (95% confidence interval) for different everolimus treatment regimen vs. control.

Outcome	Control	Everolimus + Reduced dose CNI	p value	Everolimus + CNI-withdrawal	p value
Graft loss					
Unadjusted	1.00	1.28 (0.75-2.17)	0.4	1.15 (0.60-2.20)	0.7
Adjusted*	1.00	1.26 (0.73-2.16)	0.4	0.96 (0.48-1.92)	0.9
Mortality					
Unadjusted	1.00	1.20 (0.60-2.30)	0.6	1.23 (0.54 – 2.77)	0.6
Adjusted*	1.00	1.37 (0.69-2.72)	0.4	1.20 (0.52-2.79)	0.7
Death-censored graft loss					
Unadjusted	1.00	1.54 (0.76-3.10)	0.2	0.88 (0.33 – 2.28)	0.8
Adjusted*	1.00	1.16 (0.56-2.39)	0.7	0.63 (0.21-1.8)	0.4

*Model covariates are: age at time of transplantation, gender, smoking and log-years on dialysis
CNI = calcineurin inhibitor

Table S3 – Subgroup analyses: Hazard ratio (95% confidence interval) for different early or late everolimus initiation vs. control

Outcome	Control	Early initiation	p value	Late initiation	p value
Graft loss					
Unadjusted	1.00	1.39 (0.75-2.60)	0.3	1.06 (0.47-2.43)	0.9
Adjusted*	1.00	1.42 (0.74-2.73)	0.3	0.73 (0.29-1.83)	0.5
Mortality					
Unadjusted	1.00	1.20 (0.56-2.59)	0.6	1.19 (0.38-3.76)	0.8
Adjusted*	1.00	1.41 (0.63-3.12)	0.4	1.21 (0.37-3.94)	0.8
Death-censored graft loss					
Unadjusted	1.00	1.61 (0.66-3.95)	0.3	1.1 (0.38-3.1)	0.9
Adjusted*	1.00	1.43 (0.58-3.52)	0.4	0.95 (0.32-2.8)	0.9

*Model covariates are: age at time of transplantation, gender, smoking and log-years on dialysis

Early initiation = de novo or early (<6 month) conversion trials

Late initiation = late (>6 month) conversion trials

Table S4 – On-treatment analysis for de novo and early conversion trials: Hazard ratio (95% confidence interval) for graft loss, mortality and death-censored graft

Outcome	Control	Everolimus	p value
Graft loss			
Unadjusted	1.00	0.64 (0.26-1.60)	0.3
Adjusted*	1.00	0.86 (0.34-2.16)	0.7
Mortality			
Unadjusted	1.00	0.72 (0.25-2.12)	0.6
Adjusted*	1.00	1.02 (0.35-3.02)	1.0
Death-censored graft loss			
Unadjusted	1.00	0.94 (0.26-3.34)	0.9
Adjusted*	1.00	1.06 (0.31-3.67)	0.9

*Model covariates are: age at time of transplantation, gender, smoking and log-years on dialysis

On-treatment patients = those who remained on their assigned treatment groups at 2-years after transplantation.

Table S5 – Sensitivity analyses using stratified Cox Model for primary outcomes: Hazard ratio (95% confidence interval)

Outcome	Control	Everolimus	p value
Graft loss			
Unadjusted	1.00	1.21 (0.73-2.03)	0.5
Adjusted*	1.00	1.15 (0.68-1.97)	0.6
Mortality			
Unadjusted	1.00	1.23 (0.64-2.37)	0.5
Adjusted*	1.00	1.60 (0.80-3.2)	0.2
Death-censored graft loss			
Unadjusted	1.00	1.24 (0.61-2.49)	0.6
Adjusted*	1.00	0.93 (0.45-1.93)	0.9

*Model covariates are: age at time of transplantation, gender, smoking and log-years on dialysis

Table 6 – Sensitivity analyses using stratified Cox Model for primary outcomes, using delayed entry (left-truncation) analysis: Hazard ratio (95% confidence interval)

Outcome	Control	Everolimus	p value
Graft loss			
Unadjusted	1.00	1.20 (0.72-2.00)	0.5
Adjusted*	1.00	1.15 (0.67-1.96)	0.6
Mortality			
Unadjusted	1.00	1.19 (0.62-2.30)	0.6
Adjusted*	1.00	1.34 (0.67-2.65)	0.4
Death-censored graft loss			
Unadjusted	1.00	1.20 (0.60-2.42)	0.6
Adjusted*	1.00	1.01 (0.49-2.11)	0.9

*Model covariates are: age at time of transplantation, gender, smoking and log-years on dialysis